AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions and listings of claims in the application.

1. (Currently amended) A polymer composition comprising:

a linear biocompatible polymer including a plurality of inclusion hosts,

linking molecules, each linking molecule comprising a PEG moiety and at least two adamantane moieties that form inclusion complexes with the inclusion hosts, and

at least one therapeutic agent ~~or prodrug form thereof~~,

wherein the linking molecules crosslink the polymer solely through inclusion complexes; and

wherein the therapeutic agent ~~or prodrug form thereof~~ is covalently attached to an adamantane moiety ~~a moiety that forms an inclusion complex with the inclusion host~~.

2. (Previously presented) The polymer composition of claim 1, wherein the inclusion hosts are cyclodextrin moieties.

3. (Cancelled)

4. (Previously presented) The polymer composition of claim 1, wherein the therapeutic agent is a nucleic acid.

5. (Previously presented) The polymer composition of claim 4, wherein the nucleic acid is provided in a delivery system selected from a virus, a polymer, and a liposome.

6. (Cancelled)

7. (Currently Amended) The polymer composition of claim 1, wherein the therapeutic agent is a protein, a polypeptide, or a small organic molecule.

8. (Cancelled)

9. (Previously presented) The polymer composition of claim 1, wherein the therapeutic agent is a protein or polypeptide.

10-12. (Cancelled)

13. (Previously presented) The polymer composition of claim 1, further comprising at least one adjuvant.

14. (Previously presented) The polymer composition of claim 1, further comprising an adjuvant that increases the effectiveness of the therapeutic agent.

15-30. (Cancelled)

31. (Previously presented) The polymer of claim 1, wherein the linking molecules crosslink the polymer intramolecularly.

32. (Previously presented) The polymer of claim 1, wherein the linking molecules crosslink the polymer intermolecularly.

33-34. (Cancelled)

35. (Previously presented) The polymer composition of claim 2, wherein the cyclodextrin moieties are within the polymer chain.

36. (Currently Amended) The polymer composition of claim 2, wherein the cyclodextrin moieties are ~~appended to~~ pendant from the polymer chain.

37. (New) The polymer composition of claim 1, wherein the linear biocompatible polymer is biodegradable.

38. (New) The polymer composition of claim 1, wherein the linking molecule comprises at least three adamantane moieties.